Study aim: The purpose of this study is, selecting the drugs which can use for the long-term treatment of rheumatoid arthritis while preserving therapeutic effects with fewer complications. Design: a Phase 3 and double-blind study on 60 patients aged 18 to 72 years, in two therapeutic groups each one contain 30 patients treated with curcumin and placebo tablets, in which patients and researchers do not know which patient gets the placebo and who gets the original drug Settings and conduct: Patients will be registered at Ghaem Hospital so it is a single central study. Actually the study is conducted at Clinic of Ghaem Hospital and the Rheumatic Disease Research Center of Mashhad University of Medical Sciences. The study is double blind, patients and researchers have no information about whether the drug or placebo is given to the patient. The only one who knows is the analyzer . Participants/Inclusion and exclusion criteria: The main inclusion criteria are the diagnosis of rheumatism and personal satisfaction, and the main exclusion criteria are effected kidney disease, liver failure and diabetes, as well as having a history of curcumin allergy. pregnancy and Breast feeding Intervention groups: Mentioned drug (Curcumin Drug) and placebo are given as 80 mg nanomimes (capsules of 80 mg) per day for 3 months were intake by patients. Main outcome variables: Clinical symptoms and the disease activity before starting treatment based on DAS 28 criteria and beyond.